Citable filing context
MOH's research view summarizes recent SEC filing context, starting with earnings from Jul 22, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 22, 2026 | earnings | Molina Healthcare reported Q2 2026 financial results and increased its full-year 2026 adjusted earnings guidance. |
| Jun 10, 2026 | material_agreement | Molina Healthcare's Illinois subsidiary was awarded a HealthChoice Illinois Medicaid Managed Care program contract. |
| May 11, 2026 | other | Molina Healthcare stockholders approved an equity plan increase and an amendment allowing 20% shareholders to call special meetings. |
| Jul 22, 2026 | Guidance: adjusted_eps | 5.25 to not reported |
| Jul 22, 2026 | Guidance: gaap_eps | 2.15 to not reported |
| Jul 22, 2026 | Guidance: premium_revenue | 42000.00 to 42000.00 |
| Jul 23, 2026 | mda_quarterly | Molina Healthcare reported second-quarter 2026 net income of $60 million, a significant decline from $255 million in the prior-year period. This performance reflects a challenging medical cost environment, evidenced by a consolidated medical care ratio (MCR) of 92.2%, up 180 basis points year-over-year. Premium revenue fell 6% to $10.2 billion, driven by a 14% reduction in total membership to 4.9 million, resulting from Medicaid market contraction, the expiration of the Virginia Medicaid contract, and a deliberate product and pricing strategy to restore margins in the Marketplace segment. Operating income was further impacted by a $93 million impairment charge related to the company’s strategic decision to exit the Medicare Advantage Prescription Drug (MAPD) product by 2027 to focus exclusively on dual-eligible members. While Medicaid and Medicare segments face ongoing cost pressures, Molina continues to secure new business, including recent contract wins in Wisconsin, Illinois, and Florida. Management expects further enrollment declines in 2026 as it prioritizes margin restoration over volume. Liquidity remains supported by $9.2 billion in cash and investments, though a recent S&P credit rating downgrade to "BB-" may increase future borrowing costs. The company remains focused on integrating dual-eligible programs and navigating regulatory shifts from the One Big Beautiful Bill Act. |
| Apr 23, 2026 | mda_quarterly | Molina Healthcare reported a significant decline in first-quarter 2026 net income to $14 million and diluted EPS to $0.27, compared to $298 million and $5.45 in the prior year. Membership decreased 12% to 5.0 million, driven by general Medicaid market contraction, the expiration of the Virginia Medicaid contract, and a strategic pricing shift in the Marketplace to restore margins. Premium revenue fell 4% to $10.2 billion, while the consolidated medical care ratio (MCR) rose to 91.1% amid high utilization. The company recognized a $93 million impairment charge related to its planned 2027 exit from the MAPD product to focus exclusively on dual-eligible Medicare members. Key regulatory headwinds include the One Big Beautiful Bill Act, which is expected to reduce Medicaid Expansion enrollment by 15% to 20% by 2029, and the Marketplace Program Integrity and Affordability Rule. Operationally, the company successfully transitioned MMP members in five states to integrated dual eligible special needs plans. In April 2026, S&P downgraded the company's senior notes to BB-. Liquidity remains stable with $9.6 billion in cash and investments and $1.25 billion in available credit facility capacity. |
Source: SEC EDGAR filing text and events; period Jul 22, 2026; filed Jul 22, 2026.
MOH company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.